Cargando…

Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies

Triple negative breast cancer (TNBC) is classically treated with combination chemotherapies. Although, initially responsive to chemotherapies, TNBC patients frequently develop drug-resistant, metastatic disease. Chemotherapy resistance can develop through many mechanisms, including induction of a tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakrabarty, Anindita, Chakraborty, Shayantani, Bhattacharya, Ranjini, Chowdhury, Goutam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264500/ https://www.ncbi.nlm.nih.gov/pubmed/34249714 http://dx.doi.org/10.3389/fonc.2021.674354

Ejemplares similares

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
por: Si, Wentao, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer
por: Bhatt, Akshita B., et al.
Publicado: (2019)

DCST1-AS1 Promotes TGF-β-Induced Epithelial–Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1
por: Tang, Li, et al.
Publicado: (2020)

TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/β-Catenin Pathway
por: Liu, Weiguang, et al.
Publicado: (2019)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
por: Cao, Jun, et al.
Publicado: (2021)

DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
por: Ogbu, Stella C., et al.
Publicado: (2021)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
por: Cao, Jun, et al.
Publicado: (2021)

A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario
por: Nahvi, Insha, et al.
Publicado: (2022)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Editorial: New strategies to tackle chemoresistance in cancer
por: De Marco, Carmela, et al.
Publicado: (2022)

Editorial: Strategies in overcoming the chemoresistance in colorectal cancer
por: Vodenkova, Sona, et al.
Publicado: (2023)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
por: He, Lin, et al.
Publicado: (2021)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer
por: Thankamony, Archana P., et al.
Publicado: (2023)

Clinicopathological Characteristics and Treatment Strategies of Triple-Negative Breast Cancer Patients With a Survival Longer than 5 Years
por: Xie, Ning, et al.
Publicado: (2021)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
por: Mast, Jesse M., et al.
Publicado: (2018)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Aranza-Martínez, Alberto, et al.
Publicado: (2021)

Understanding and harnessing triple-negative breast cancer-related microbiota in oncology
por: Devoy, Ciaran, et al.
Publicado: (2022)

Correlation between the Warburg effect and progression of triple-negative breast cancer
por: Liu, Shaojun, et al.
Publicado: (2023)

Knockdown of SPON2 inhibits the growth of triple-negative breast cancer
por: Hu, Xueyi, et al.
Publicado: (2023)

Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K–AKT Pathway
por: Zhang, Daoyu, et al.
Publicado: (2020)

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway
por: Wang, Kai-nan, et al.
Publicado: (2022)

USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1
por: Lin, Yueh-Te, et al.
Publicado: (2022)

Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
por: Wani, Tasaduq H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_geg9t3mpr82alohv8vivs59crm